Category Archives: Europe

The Nordic Region’s “Star” Companies

Three companies were crowned the Nordic region’s “shining examples of innovative life science companies” in Stockholm, Sweden, this week.  Nordic Life Science Days, the region’s largest partnering conference, gave its annual Nordic Star Awards to Bone Index (Kuopio, Finland), Lytix Biopharma (Oslo, Norway) and PledPharma (Stockholm, Sweden). Bone Index was noted for its osteoporosis diagnostic, Bindex, while Lytix Biopharma […]
Also posted in Biotech | Tagged , , , | Leave a comment

The Transatlantic Trade and Investment Partnership: From Hot TTIP to Oblivion?

Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies — and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story. But as summer […]
Also posted in Global | Tagged , , , , , | Leave a comment

EuropaBio’s Most Innovative Biotechs 2014

EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium. Shortlisted are: 
Also posted in Biotech, Events | Tagged , , , | Leave a comment

Major Changes to EU Clinical Trials Regulation

Earlier this year, the newly approved EU Clinical Trials regulation (No 536/2014) was published in the Official Journal of the EU (OJEU).  The European Commission (EC) estimates that all the changes could save researchers €800 million (over $1 billion) a year. It replaces the existing EU Clinical Trials Directive (2001/20/EC), which was intended to simplify […]
Also posted in Global, Guest Blog, R&D, Regulatory | Tagged , , , , | Leave a comment

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Also posted in Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta